中华内分泌代谢杂志
中華內分泌代謝雜誌
중화내분비대사잡지
CHINESE JOURNAL OF ENDOCRINOLOGY AND METABOLISM
2008年
5期
529-530
,共2页
格雷夫斯病%碘放射性同位素%促甲状腺素受体抗体
格雷伕斯病%碘放射性同位素%促甲狀腺素受體抗體
격뢰부사병%전방사성동위소%촉갑상선소수체항체
Graves' disease%Iodine radioisotopes%Thyrotropin receptor antibodies
对157例Graves病131I门诊治疗的病例进行回顾性研究.按131I治疗1年后甲状腺功能状态分成3组:缓解组(FT3、FT4)、部分缓解组(FT3、FT3未降至正常范围)、甲减组(FT3、FT3低于正常).治疗前促甲状腺素受体抗体(TRAb)的阳性率为88.5%.131I治疗后,TRAb在3～6个月时达高峰,之后逐渐下降.甲状腺重量、显著升高的TRAb(≥405 U/L)、FT3、FT3水平是评估预后的指标.
對157例Graves病131I門診治療的病例進行迴顧性研究.按131I治療1年後甲狀腺功能狀態分成3組:緩解組(FT3、FT4)、部分緩解組(FT3、FT3未降至正常範圍)、甲減組(FT3、FT3低于正常).治療前促甲狀腺素受體抗體(TRAb)的暘性率為88.5%.131I治療後,TRAb在3～6箇月時達高峰,之後逐漸下降.甲狀腺重量、顯著升高的TRAb(≥405 U/L)、FT3、FT3水平是評估預後的指標.
대157례Graves병131I문진치료적병례진행회고성연구.안131I치료1년후갑상선공능상태분성3조:완해조(FT3、FT4)、부분완해조(FT3、FT3미강지정상범위)、갑감조(FT3、FT3저우정상).치료전촉갑상선소수체항체(TRAb)적양성솔위88.5%.131I치료후,TRAb재3～6개월시체고봉,지후축점하강.갑상선중량、현저승고적TRAb(≥405 U/L)、FT3、FT3수평시평고예후적지표.
One hundred and fifty-seven patients with Graves' disease treated with 131I from July 2001 to March 2003 were studied retrospectively. According to the thyroid function one year after 131I therapy, the patients were divided into 3 groups: remission group with normal FT3, FT4, partial remission group with above normal levels of FT3, FT4, and hypothyroid group with lowered levels of FT3, FT4. Prior to 131I treatment the thyroid-stimulating hormone receptor antibody (TRAb) was positive in 88.5% of the patients. After the therapy, TRAb levels rose transiently and reached the peak within 3-6 months and then dropped gradually thereafter. The weight of pretreatment thyroid, high levels of TRAb (≥405 U/L) and FT3, FT4 were predictors for the outcome of treatment.
